Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Ecotoxicology and Environmental Safety|April 21, 2019
Organochlorine and organophosphorous pesticides may induce colorectal cancer; A case-control studyMoslem Abolhassani, Gholamreza Asadikaram, Parisa Paydar, et al.Journal of Cellular Biochemistry|April 23, 2019
Organochlorine and organophosphorus pesticides and bladder cancer: A case-control studyNeda Mortazavi, Gholamreza Asadikaram, Mohammad-Reza Ebadzadeh, et al.Scientific Reports|September 12, 2024
Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trialAliasghar Tirgar, Masoud Rezaei, Mohammadhadi Ehsani, et al.Complementary Therapies in Clinical Practice|April 21, 2019
The prevalence and predictors of using herbal medicines among Iranian cancer patientsMaliheh Sadat Bazrafshani, Behjat Kalantari Khandani, Abbas Pardakhty, et al.Asian Pacific Journal of Cancer Prevention : APJCP|August 29, 2024
The Association between Allergy and Cancer: A Case-Control StudyMohammad Aryaie, Vahid Moazed, Ali-Akbar Haghdost, et al.Asian Pacific Journal of Cancer Prevention : APJCP|March 28, 2020
Opium Use and Head and Neck Cancers: A Matched Case-Control Study in IranHosniyeh Alizadeh, Ahmad Naghibzadeh Tahami, Narges Khanjani, et al.BMC Pharmacology & Toxicology|July 28, 2022
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patientsReza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, et al.Acta Oncologica (Stockholm, Sweden)|November 7, 2023
Opium use and risk of colorectal cancer: a multi-center case-referent study in IranMaryam Hadji, Maryam Marzban, Hamideh Rashidian, et al.BMC Cancer|September 7, 2022
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trialAbolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, et al.Pageof 3